Phase 1/2 study of LY3537982, a KRAS G12C inhibitor, in advanced solid tumors.

This open-label trial, sponsored by Eli Lilly and Company, evaluates LY3537982 alone or with agents like pembrolizumab in patients with unresectable advanced or metastatic solid tumors harboring KRAS G12C mutations, including NSCLC (stage IIIB-IV) and others. The study aims to define safety, dosing, and preliminary effectiveness.